<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00836225</url>
  </required_header>
  <id_info>
    <org_study_id>ISIS 388626-CS1</org_study_id>
    <nct_id>NCT00836225</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Activity Study of Multiple Doses of ISIS-SGLT2Rx in Healthy Volunteers</brief_title>
  <official_title>A Phase I , Double-Blind, Placebo-Controlled, Dose-Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of ISIS 388626 Administered to Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ionis Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ionis Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary purpose of this trial is to assess the safety and tolerability of ISIS-SGLT2Rx
      when given at increasing single doses and to assess the safety and tolerability of the same
      doses when given multiple times.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To evaluate the safety and tolerability of a single subcutaneous injection of ISIS-SGLT2Rx
      administered at four increasing dose levels (50, 100, 200, 400 mg) and to evaluate the safety
      and tolerability of multiple doses of ISIS 388626 administered subcutaneously of either 6 or
      13 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2009</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate the safety and tolerability of single and multiple doses of ISIS-SGLT2Rx administered subcutaneously</measure>
    <time_frame>30 days for single dose, 11 weeks for 6-week dosing, 18 weeks for 13-week dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile all doses and Pharmacodynamics for multi-dose groups</measure>
    <time_frame>3 days for single dose, 11 weeks for 6-week dosing, 18 weeks for 13-week dosing</time_frame>
  </secondary_outcome>
  <number_of_arms>10</number_of_arms>
  <enrollment type="Actual">103</enrollment>
  <condition>Type 2 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ISIS 388626 vs Placebo, s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ISIS 388626 vs Placebo, s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ISIS 388626 vs Placebo, s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>400 mg ISIS 388626 vs Placebo, s.c. injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ISIS 388626, 3x over 1 week s.c. injection, weekly s.c. injection for 5 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>AAA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BBB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>100 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CCC</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>200 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FFF</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>50 mg ISIS 388626, weekly s.c. injection for 13 weeks vs Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ISIS 388626</intervention_name>
    <description>4 arms of single dose s.c. injections: A 50 mg, B 100 mg, C 200 mg, D 400 mg, 2 arms of multi-dose: 3 s.c. injections over 1 week followed by 5 weekly s.c. injections: AA 50 mg, BB 100 mg 3 arms of multi-dose 13 weekly s.c. injections: AAA 50 mg, BBB 100 mg, CCC 200 mg, FFF 50 mg
Placebo: 0.9% sterile saline</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
    <arm_group_label>C</arm_group_label>
    <arm_group_label>D</arm_group_label>
    <arm_group_label>AA</arm_group_label>
    <arm_group_label>BB</arm_group_label>
    <arm_group_label>AAA</arm_group_label>
    <arm_group_label>BBB</arm_group_label>
    <arm_group_label>CCC</arm_group_label>
    <arm_group_label>FFF</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18 to 65 years

          -  Male or female gender although females must be post-menopausal or surgically sterile
             (hysterectomy, oophorectomy or tubal ligation)

          -  Give written informed consent to participate in the study and availability for all
             study requirements

          -  Fasting plasma glucose &lt;/= the upper limit of the laboratory's reference range (ULN)

          -  HbA1c &lt;/= ULN

          -  BMI &lt; 30 kg/m²

          -  Agree to maintain steady hydration throughout study participation and agree not to
             fluid restrict

        Exclusion Criteria:

          -  Pregnant women, nursing mothers or women of childbearing potential

          -  Clinically significant abnormalities in medical history or physical examination

          -  Clinically significant abnormalities in laboratory examination (including ALT &gt; ULN,
             AST &gt; ULN, bilirubin &gt; ULN, creatinine &gt; ULN, urine protein positive by urine
             dipstick, platelets &lt; lower limit of normal and any other clinically significant
             laboratory findings)

          -  Estimated GFR &lt; 60 mL/min per 1.73m²

          -  History of clinically significant abnormalities in coagulation parameters

          -  Positive test result for HIV, hepatitis B virus, and/or hepatitis C virus

          -  Active infection requiring antiviral or antimicrobial therapy

          -  Subjects on chronic or acute prescription medication may be permitted after discussion
             with the Isis Medical Monitor

          -  Malignancy (with the exception of basal or squamous cell carcinoma of the skin if
             adequately treated and no recurrence for &gt; 1 year)

          -  Any other concurrent condition which, in the opinion of the Investigator, would
             preclude participation in this study or interfere with compliance

          -  Past and present history of alcohol or drug abuse (defined as &gt; 3 units daily)

          -  Undergoing or have undergone treatment with another investigational drug, biologic
             agent or device within 90 days prior to Screening

          -  Blood donation within three months of Screening
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adam Cohen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Center for Human Drug Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Center for Human Drug Research</name>
      <address>
        <city>Leiden</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 2, 2009</study_first_submitted>
  <study_first_submitted_qc>February 2, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 4, 2009</study_first_posted>
  <last_update_submitted>February 2, 2012</last_update_submitted>
  <last_update_submitted_qc>February 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 3, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>SGLT2 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

